+

WO2006018850A2 - Compositions et leurs methodes d'utilisation dans le traitement de maladies associees aux amyloides - Google Patents

Compositions et leurs methodes d'utilisation dans le traitement de maladies associees aux amyloides Download PDF

Info

Publication number
WO2006018850A2
WO2006018850A2 PCT/IL2005/000902 IL2005000902W WO2006018850A2 WO 2006018850 A2 WO2006018850 A2 WO 2006018850A2 IL 2005000902 W IL2005000902 W IL 2005000902W WO 2006018850 A2 WO2006018850 A2 WO 2006018850A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen
indole
hydroxy
manufacture
Prior art date
Application number
PCT/IL2005/000902
Other languages
English (en)
Other versions
WO2006018850A3 (fr
Inventor
Ehud Gazit
Tomer Cohen
Original Assignee
Tel Aviv University Future Technology Development L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Aviv University Future Technology Development L.P. filed Critical Tel Aviv University Future Technology Development L.P.
Priority to AT05774727T priority Critical patent/ATE539745T1/de
Priority to US11/660,522 priority patent/US7732479B2/en
Priority to EP05774727A priority patent/EP1793816B1/fr
Publication of WO2006018850A2 publication Critical patent/WO2006018850A2/fr
Publication of WO2006018850A3 publication Critical patent/WO2006018850A3/fr
Priority to US12/794,746 priority patent/US8889729B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms

Definitions

  • Destabilizing compounds Heparin sulfate has been identified as a component of all amyloids and has also been implicated in the earliest stages of inflammation associated amyloid induction. Kisilevsky and co-workers (Mature Med. 1:143-148, 1995) described the use of low molecular weight anionic sulfonate or sulfate compounds that interfere with the interaction of heparin sulfate with the inflammation associated amyloid precursor and the ⁇ peptide of Alzheimer's disease (AD).
  • AD Alzheimer's disease
  • 20020086067 and 20020151506 teach the use of various components of green tea extracts for treating an amyloid disease. While these patent applications teach that these components inhibit amyloid fibril formation, they fail to teach neither a mechanism nor a common structural feature which provides these green tea components with such an activity.
  • the present inventor has previously shown that aromatic interactions play a key role in amyloid fibril formation by serving as structural and functional elements that direct molecular recognition and self-assembly and have further shown that such aromatic interactions can be induced by tryptophane containing peptide sequences [Gazit (2002) FASEB J. 16:77-83].
  • indole derivatives such as indole-3-carbinol (3-hydroxymethyl indole), 3-hydroxyindole, and 4-hydroxyindole, suggesting use of various indole compounds in the treatment of amyloid associated diseases.
  • each R 7 and R 9 is hydroxyalkyl, the compound being a 2,3-dihydroxyalkyl indole.
  • the pharmaceutical composition further comprises an anti-amyloid drug.
  • an article-of-manufacture comprising a packaging material and a pharmaceutical composition identified for treating amyloid associated diseases being contained within the packaging material, the pharmaceutical composition including, as an active ingredient, the compound described hereinabove, and a pharmaceutically acceptable carrier.
  • the term 'alkyl' refers to a saturated aliphatic hydrocarbon including straight chain and branched chain groups.
  • the alkyl group has 1 to 20 carbon atoms.
  • the alkyl is a medium size alkyl having 1 to 10 carbon atoms.
  • the alkyl is a lower alkyl having 1 to 4 carbon atoms.
  • the term 'hydroxyphenol 1 which also encompasses the term 'dihydroxyphenol' refers to a phenol, as defined hereinabove, which is further substituted by one or more additional hydroxy groups.
  • the additional hydroxy groups can be at the para, ortho and/or meta positions with respect to the hydroxy group of the phenol.
  • the hydroxyphenol may be additionally substituted or unsubstituted.
  • 'phosphinyl' describes a -PR'- group, with R' as defined hereinabove.
  • Preferred electronegative groups according to the present embodiments include halo and hydroxy, as these terms are defined herein.
  • the method includes administering to a subject in need thereof, a therapeutically effective amount of the compound described hereinabove, a pharmaceutically acceptable salt thereof, or a prodrug thereof, thereby treating the amyloid associated disease in the subject.
  • Preferred individual subjects according to the present invention are mammals such as canines, felines, ovines, porcines, equines, and bovines.
  • Preferably the individual subjects according to the present invention are humans.
  • the term 'treating' refers to reducing or preventing amyloid plaque formation, or substantially decreasing plaque occurrence in an affected tissue.
  • Amyloid associated diseases treated according to the present invention include, but are not limited to, type II diabetes mellitus, Alzheimer's disease (AD), early onset Alzheimer's disease, late onset Alzheimer's disease, presymptomatic Alzheimer's disease, Parkinson's disease, SAA amyloidosis, hereditary Icelandic syndrome, multiple myeloma, medullary carcinoma, aortic medical carcinoma, Insulin injection amyloidosis, prion-systematic amyloidosis, choronic inflammation amyloidosis, Huntington's disease, senile systemic amyloidosis, pituitary gland amyloidosis, Hereditary renal amyloidosis, familial British dementia, Finnish hereditary amyloidosis, familial non-neuropathic amyloidosis [Gazit (2002) Curr.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • late onset Alzheimer's disease presymptomatic Alzheimer's disease
  • Parkinson's disease Parkinson's disease
  • the term 'prodrug' refers to an agent, which is converted into the active compound (the active parent drug) in vivo.
  • Prodrugs are typically useful for facilitating the administration of the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not.
  • the prodrug may also have improved solubility as compared with the parent drug in pharmaceutical compositions.
  • Prodrugs are also often used to achieve a sustained release of the active compound in vivo.
  • An example, without limitation, of a prodrug would be a compound of the present invention, having one or more phenol moieties, which is administered as an ester (the 'prodrug'). Such a prodrug is hydrolysed in vivo, to thereby provide the free compound (the parent drug).
  • the selected ester may affect both the solubility characteristics and the hydrolysis rate of the prodrug.
  • a 'pharmaceutical composition' refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to the subject treated.
  • the term 'active ingredient' refers to the compound, which is accountable for the biological effect.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • TEM Transmission Electron Microscopy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention porte sur des dérivés d'indole, sur des compositions les comprenant et sur leurs méthodes d'utilisation dans le traitement de maladies associées aux amyloïdes telles que le diabète sucré de type II, la démence ou la maladie d'Alzheimer, l'amylose systémique et localisée et des encéphalopathies associées aux prions.
PCT/IL2005/000902 2004-08-19 2005-08-18 Compositions et leurs methodes d'utilisation dans le traitement de maladies associees aux amyloides WO2006018850A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT05774727T ATE539745T1 (de) 2004-08-19 2005-08-18 Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
US11/660,522 US7732479B2 (en) 2004-08-19 2005-08-18 Compositions for treating amyloid associated diseases
EP05774727A EP1793816B1 (fr) 2004-08-19 2005-08-18 Compositions pour le traitement de maladies associées à l'amyloide
US12/794,746 US8889729B2 (en) 2004-08-19 2010-06-06 Compositions for treating amyloid associated diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60263504P 2004-08-19 2004-08-19
US60/602,635 2004-08-19
US64957405P 2005-02-04 2005-02-04
US60/649,574 2005-02-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/660,522 A-371-Of-International US7732479B2 (en) 2004-08-19 2005-08-18 Compositions for treating amyloid associated diseases
US12/794,746 Continuation US8889729B2 (en) 2004-08-19 2010-06-06 Compositions for treating amyloid associated diseases

Publications (2)

Publication Number Publication Date
WO2006018850A2 true WO2006018850A2 (fr) 2006-02-23
WO2006018850A3 WO2006018850A3 (fr) 2006-08-10

Family

ID=35462220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000902 WO2006018850A2 (fr) 2004-08-19 2005-08-18 Compositions et leurs methodes d'utilisation dans le traitement de maladies associees aux amyloides

Country Status (4)

Country Link
US (2) US7732479B2 (fr)
EP (1) EP1793816B1 (fr)
AT (1) ATE539745T1 (fr)
WO (1) WO2006018850A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534791B2 (en) 2005-06-17 2009-05-19 H. Lundbeck A/S Benzo[b]furane and benzo[b]thiophene derivatives
EP2061459A2 (fr) * 2006-08-23 2009-05-27 Intellect Neurosciences Inc. Sel de calcium de l'acide 3-(3-indolyl)propionique et méthode de fabrication de l'acide libre de l'acide 3-(3-indolyl)propionique à partir dudit sel
US7563908B2 (en) 2003-12-23 2009-07-21 Jan Kehler 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
US8889729B2 (en) 2004-08-19 2014-11-18 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9486439B2 (en) 2013-06-24 2016-11-08 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
WO2022260491A1 (fr) * 2021-06-11 2022-12-15 주식회사 메타센테라퓨틱스 Nouveau dérivé d'indole et son utilisation pour le traitement de maladies liées à des produits finaux de glycation avancée
WO2022260492A1 (fr) * 2021-06-11 2022-12-15 주식회사 메타센테라퓨틱스 Composition comprenant un dérivé d'indole pour la prévention d'une maladie liée aux produits finaux de glycation avancée

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
DE602004020179D1 (de) * 2003-01-07 2009-05-07 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben
JP5137400B2 (ja) * 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
WO2006006172A2 (fr) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Utilisation d'agents anti-amyloides pour traiter et determiner des infections pathogenes
WO2006013552A2 (fr) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles de nanostructures a base de peptides et leur procede de formation
US9096645B2 (en) 2010-11-15 2015-08-04 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
EP2694057B1 (fr) * 2011-04-01 2019-06-05 SRI International Inhibiteurs de lipoxygénase
WO2022010352A1 (fr) * 2020-07-10 2022-01-13 Rijksuniversiteit Groningen 5-hydroxyindole et ses analogues utilisés comme stimulants de la motilité intestinale

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042102A1 (fr) 1998-02-23 1999-08-26 South Alabama Medical Science Foundation Utilisations d'acides indole-3-propioniques et de sels ou d'esthers de ces acides comme medicaments
US20010041732A1 (en) 1998-05-04 2001-11-15 David Gurley Use
US20020086067A1 (en) 1999-12-30 2002-07-04 Choi Paula Y. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
US20020151506A1 (en) 2000-12-29 2002-10-17 Castillo Gerardo M. Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
WO2003039540A2 (fr) 2001-11-09 2003-05-15 Sepracor Inc. Inhibiteurs de d-amino acide oxydase destines a l'apprentissage et a la memoire
WO2003070269A1 (fr) 2002-02-18 2003-08-28 Cevec Pharmaceuticals Gmbh Traitement de maladies de l'oeil, de l'oreille interne et du systeme nerveux central

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920080A (en) 1960-01-05 Process of preparing tryptamine
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
BE638366A (fr) * 1963-10-09
FR1540484A (fr) 1967-08-17 1968-09-27 Pasteur Institut Préparation de dérivés oxygénés de l'indole
US3976639A (en) 1970-11-04 1976-08-24 Hoffmann-La Roche Inc. Intermediates for indoles
US3790596A (en) * 1971-05-14 1974-02-05 V Shkilkova Method of producing indole and substitution products of the same
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
PH14917A (en) 1978-10-23 1982-01-29 Abbott Lab Anti-bacterial peptide
DE2905531A1 (de) * 1979-02-14 1981-01-08 Boehringer Mannheim Gmbh Diagnostisches mittel zum nachweis von leukozyten in koerperfluessigkeiten
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DE3233679A1 (de) 1981-12-08 1984-03-08 Wilhelm Dr.med. 8900 Augsburg Meyer-Glauner Carrier-tripeptid mit antifungischer wirksamkeit
JPS5944313A (ja) 1982-09-07 1984-03-12 Yakult Honsha Co Ltd 抗菌性組成物
JPS6040061A (ja) 1983-08-12 1985-03-02 ユニチカ株式会社 抗菌剤徐放性導尿カテ−テル
US4626540A (en) 1983-11-08 1986-12-02 Warner-Lambert Company Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3412445C2 (de) 1984-03-31 1986-10-30 Wilhelm Dr. 7400 Tübingen Meyer-Glauner Tripeptid und dieses enthaltende antifungische Mittel
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
JPS6344895A (ja) 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドａ蛋白質単クロ−ン性抗体
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4970233A (en) 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH02295923A (ja) 1989-05-10 1990-12-06 Taiyo Kagaku Co Ltd 腸内クロストリジウム属細菌の増殖阻害剤
IT1237472B (it) 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2919142B2 (ja) * 1990-12-27 1999-07-12 株式会社東芝 感光性組成物およびそれを用いたパターン形成方法
DE4101895C1 (fr) * 1991-01-23 1991-12-05 Forschungszentrum Juelich Gmbh, 5170 Juelich, De
JPH06506941A (ja) 1991-04-24 1994-08-04 ワーナー−ランバート・コンパニー α−置換アミノ酸含有ＣＣＫ類似体
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
WO1994005311A1 (fr) * 1992-08-27 1994-03-17 Deakin Research Limited Analogues peptidiques de synthese a modifications retro, inverse ou retro-inverse
EP0710228B1 (fr) 1993-07-19 1998-01-21 Resolution Pharmaceuticals Inc. Chelateurs de radionucleides de type hydrazino presentant une configuration n 3?s
ATE250628T1 (de) * 1993-10-14 2003-10-15 Scripps Research Inst Rohr bestehend aus zyklischen peptiden
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1996030395A2 (fr) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Inhibiteur de la protease de cysteine
CA2227732A1 (fr) 1995-07-11 1997-01-30 Degussa Aktiengesellschaft Procede de production de peptides et peptides a protection n-carbamoyle
WO1997016191A1 (fr) 1995-11-02 1997-05-09 Warner-Lambert Company Inhibition de l'amyloidose par les 9-acridinones
WO1997019208A1 (fr) * 1995-11-22 1997-05-29 Northwestern University Procede d'encapsulation d'un materiau dans un nanotube en carbone
WO1997049722A1 (fr) 1996-06-25 1997-12-31 Nisshin Flour Milling Co., Ltd. Depsipeptides et medicaments contenant ces composes comme ingredient actif
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US6617114B1 (en) 1996-10-31 2003-09-09 Karo Bio Ab Identification of drug complementary combinatorial libraries
EP0941334B1 (fr) 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Proproteines similaires a l'exotoxine de pseudomonas, pouvant etre activees par une protease
JPH10245342A (ja) 1997-03-03 1998-09-14 Mitsui Norin Kk β−アミロイド蛋白の神経細胞毒性低減剤
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US6001868A (en) * 1997-05-30 1999-12-14 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
DE19725619A1 (de) 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
EP2180050B1 (fr) 1998-05-07 2016-04-20 Universite Libre De Bruxelles Confinement biologique à base de cytotoxine
JP3340699B2 (ja) 1998-06-05 2002-11-05 東京瓦斯株式会社 膵外分泌機能診断剤
WO2000030683A1 (fr) * 1998-11-19 2000-06-02 Shionogi & C0., Ltd. Composes prophylactiques et/ou therapeutiques destines a des maladies du systeme nerveux central et possedant des composes antagonistes du recepteur de txa2 et/ou inhibiteurs de la txa2 synthase
JP2000193661A (ja) 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk 痴呆症の検査方法
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6361861B2 (en) * 1999-06-14 2002-03-26 Battelle Memorial Institute Carbon nanotubes on a substrate
GB9916810D0 (en) 1999-07-16 1999-09-22 Cancer Res Campaign Tech Killing cells
IL147970A0 (en) 1999-08-09 2002-09-12 Tripep Ab Pharmaceutical compositions containing tripeptides
GB9922013D0 (en) 1999-09-17 1999-11-17 Univ Sussex Peptides
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
JP2003516151A (ja) 1999-11-29 2003-05-13 エイブイアイ バイオファーマ， インコーポレイテッド 細菌１６Ｓおよび２３ＳｒＲＮＡに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用
AU2289601A (en) 1999-12-21 2001-07-03 Mars, Incorporated The use of procyanidins in the modulation of cytokine gene expression and protein secretion
US20020006954A1 (en) * 2000-03-02 2002-01-17 Oklahoma Medical Research Foundation Desmethyl tocopherols for preventing or slowing degenerative neurological diseases
CN1254234C (zh) 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
DE10043282A1 (de) 2000-09-02 2002-03-28 Kurt Heininger Verwendung von Inhibitoren der Amyloid-beta-Protein-Bildung
JP3560333B2 (ja) * 2001-03-08 2004-09-02 独立行政法人 科学技術振興機構 金属ナノワイヤー及びその製造方法
ITVR20010031A1 (it) 2001-03-12 2002-09-12 Hisanori Suzuki Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative.
US20030130484A1 (en) * 2001-03-20 2003-07-10 Gordon David J. Inhibitors and disassemblers of fibrillogenesis
US7214769B2 (en) 2001-05-23 2007-05-08 The Curators Of The University Of Missouri Method for inverse solid phase synthesis of peptides
RU2196568C1 (ru) * 2001-08-08 2003-01-20 Киселев Всеволод Иванович Фармацевтическая композиция для профилактики и лечения дисплазий и рака шейки матки и папилломатоза гортани, а также способ профилактики и лечения этих заболеваний на ее основе
CA2357053A1 (fr) * 2001-09-04 2003-03-04 Unknown Efficacite d'une combinaison de substances antioxydantes pour le traitement de la maladie d'alzheimer
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US6976639B2 (en) * 2001-10-29 2005-12-20 Edc Biosystems, Inc. Apparatus and method for droplet steering
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US6803379B2 (en) 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US20040029830A1 (en) 2002-08-06 2004-02-12 Hebert Rolland F. Water-soluble indole-3-propionic acid
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
DE602004020179D1 (de) 2003-01-07 2009-05-07 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben
JP5137400B2 (ja) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
AU2003254146A1 (en) * 2003-07-24 2005-03-07 Case Western Reserve University Methods for the treatment of parkinson's disease
US7348399B2 (en) 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
EP1663199B1 (fr) 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Compositions et methodes d'utilisation de ces compositions pour le traitement des maladies associees a la substance amyloide
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
CA2558721A1 (fr) * 2004-02-27 2005-09-15 Pfizer Inc. Recepteur gpr35
US7089736B2 (en) * 2004-07-27 2006-08-15 General Motors Corporation Variable nozzle turbo (VNT) solenoid temperature estimator
US20060035890A1 (en) * 2004-08-10 2006-02-16 Amit Banerjee Compounds and methods for the treatment of ubiquitin conjugating disorders
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
EP1937260A2 (fr) * 2005-09-16 2008-07-02 University of Pittsburgh Methode in vivo et in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042102A1 (fr) 1998-02-23 1999-08-26 South Alabama Medical Science Foundation Utilisations d'acides indole-3-propioniques et de sels ou d'esthers de ces acides comme medicaments
US20010041732A1 (en) 1998-05-04 2001-11-15 David Gurley Use
US20020086067A1 (en) 1999-12-30 2002-07-04 Choi Paula Y. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
US20020151506A1 (en) 2000-12-29 2002-10-17 Castillo Gerardo M. Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
WO2003039540A2 (fr) 2001-11-09 2003-05-15 Sepracor Inc. Inhibiteurs de d-amino acide oxydase destines a l'apprentissage et a la memoire
WO2003070269A1 (fr) 2002-02-18 2003-08-28 Cevec Pharmaceuticals Gmbh Traitement de maladies de l'oeil, de l'oreille interne et du systeme nerveux central

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ALTLAND, NEUROGENETICS, vol. 2, 1999, pages 183 - 188
AZRIEL; GAZIT, J. BIOL. CHEM, vol. 276, 2001, pages 34156 - 34161
BOTH ET AL., NATURE, vol. 385, 1997, pages 787 - 93
CLEARY ET AL., NATURE NEUROSCI., vol. 8, 2004, pages 79 - 84
CURR TOP MICROBIOL IMMUNOL, vol. 172, pages 21 - 38
DONALD ET AL., INT J CANCER., vol. 111, 2004, pages 961 - 7
GAJDUSEK, SCIENCE, vol. 197, 1977, pages 943 - 960
GAZIT, FASEB J., vol. 16, 2002, pages 77 - 83
GILLMORE ET AL., BR. J. HAEMATOL., vol. 99, 1997, pages 245 - 56
GLENNER, N. ENG. J. MED., vol. 302, 1980, pages 1283 - 92
HANSEN ET AL., J. IMMUNOL. METHODS, vol. 119, 1989, pages 203 - 210
HERRAIZ ET AL., FREE RADIC RES., vol. 38, 2004, pages 323 - 31
JARRETT ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 4693 - 4697
JARRETT; LANSBURY, CELL, vol. 73, 1993, pages 1055 - 1058
KAHN ET AL., DIABETES, vol. 48, 1999, pages 241 - 53
KAYED ET AL., SCIENCE, vol. 300, 2003, pages 486 - 489
KIM ET AL., FASEB J, vol. 17, 2003, pages 118 - 120
KISILEVSKY, MATURE MED., vol. 1, 1995, pages 143 - 148
KULKARNI ET AL., J. ENDOCRINOL., vol. 151, 1996, pages 341 - 8
LAMBERT ET AL., PROC. NATL. ACAD. SCI. US.A., vol. 95, 1998, pages 6448 - 6453
MEDORI; TRITSCHLER ET AL., N ENGL J MED, vol. 326, 1992, pages 444 - 449
NAIKI ET AL., BIOCHEMISTRY, vol. 36, 1997, pages 6243 - 6250
NOVIALS ET AL., PANCREAS, vol. 17, 1998, pages 182 - 6
SOLOMON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 4109 - 12
SOTO ET AL., NAT. MED., vol. 4, 1998, pages 822 - 6
WALSH ET AL., BIOCHEM. SOC. TRANS., vol. 30, 2002, pages 552 - 557
WANG ET AL., BRAIN RES., vol. 924, 2002, pages 133 - 140

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737170B2 (en) 2003-12-23 2010-06-15 H. Lundbeck A/S Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
US7563908B2 (en) 2003-12-23 2009-07-21 Jan Kehler 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
US7652150B2 (en) 2003-12-23 2010-01-26 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs
US7737171B2 (en) 2003-12-23 2010-06-15 H. Lundbeck A/S Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
US8889729B2 (en) 2004-08-19 2014-11-18 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US7534791B2 (en) 2005-06-17 2009-05-19 H. Lundbeck A/S Benzo[b]furane and benzo[b]thiophene derivatives
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
EP2061459A4 (fr) * 2006-08-23 2010-05-26 Intellect Neurosciences Inc Sel de calcium de l'acide 3-(3-indolyl)propionique et méthode de fabrication de l'acide libre de l'acide 3-(3-indolyl)propionique à partir dudit sel
EP2061459A2 (fr) * 2006-08-23 2009-05-27 Intellect Neurosciences Inc. Sel de calcium de l'acide 3-(3-indolyl)propionique et méthode de fabrication de l'acide libre de l'acide 3-(3-indolyl)propionique à partir dudit sel
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9968588B2 (en) 2013-06-24 2018-05-15 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9486439B2 (en) 2013-06-24 2016-11-08 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US9737508B2 (en) 2013-06-24 2017-08-22 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US9737507B2 (en) 2013-06-24 2017-08-22 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US9381188B2 (en) 2013-06-24 2016-07-05 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9974769B2 (en) 2013-06-24 2018-05-22 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US9474741B2 (en) 2013-06-24 2016-10-25 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US10278953B2 (en) 2013-06-24 2019-05-07 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US10278952B2 (en) 2013-06-24 2019-05-07 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US10617671B2 (en) 2013-06-24 2020-04-14 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US10702499B2 (en) 2013-06-24 2020-07-07 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US11026920B2 (en) 2013-06-24 2021-06-08 Vyne Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
WO2022260491A1 (fr) * 2021-06-11 2022-12-15 주식회사 메타센테라퓨틱스 Nouveau dérivé d'indole et son utilisation pour le traitement de maladies liées à des produits finaux de glycation avancée
WO2022260492A1 (fr) * 2021-06-11 2022-12-15 주식회사 메타센테라퓨틱스 Composition comprenant un dérivé d'indole pour la prévention d'une maladie liée aux produits finaux de glycation avancée

Also Published As

Publication number Publication date
EP1793816A2 (fr) 2007-06-13
WO2006018850A3 (fr) 2006-08-10
US20080194667A1 (en) 2008-08-14
ATE539745T1 (de) 2012-01-15
US7732479B2 (en) 2010-06-08
US20100240726A1 (en) 2010-09-23
EP1793816B1 (fr) 2012-01-04
US8889729B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
US8889729B2 (en) Compositions for treating amyloid associated diseases
US8372880B2 (en) Compositions and methods using same for treating amyloid-associated diseases
Ho et al. Inhibitors of monoamine oxidase. Influence of methyl substitution on the inhibitory activity of β‐carbolines
FI92055C (fi) Menetelmä farmaseuttisesti aktiivisten 3-indolipalorypälehappojohdannaisten valmistamiseksi
US9359325B2 (en) Lipoyl compounds and methods for treating ischemic injury
CN1377260A (zh) 抑制淀粉样蛋白沉积的方法和化合物
US11471478B2 (en) Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
US20090011975A1 (en) Targeted bone marrow protection agents
EP1663219B1 (fr) Derives d'indole pour le traitement de maladies liees au processus d'epissage
MX2011005095A (es) Tratamiento de proteinopatias usando un inhibidor de farnesil transferasa.
JP2578098B2 (ja) 変性骨疾患の予防治療剤
EP0915696B1 (fr) COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES beta-AMYLOIDES
EP1093455A1 (fr) Derives du bis-indole et leur utilisation comme agents anti-inflammatoires
CN1974545B (zh) 长链脂肪酰胺类化合物及其应用
US20030087944A1 (en) Method for the treatment of renal dysfunction with spla2 inhibitors
EP0970080B1 (fr) Derives d'imino-aza-anthracyclinone pour traiter la degenerescence amylo de
JP4951350B2 (ja) 神経変性障害の予防及び処置のための中性エンドペプチダーゼ（ｎｅｐ）及びヒト可溶性エンドペプチダーゼ（ｈｓｅｐ）阻害剤
EP3875086A1 (fr) Doubles inhibiteurs de la nécroptose cellulaire et de la ferroptose destinés à être utilisés dans le traitement de patients ayant subi une greffe d'organes
CN100551911C (zh) 具有含氮杂环修饰的多酚化合物及其应用
US20190016679A1 (en) Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
WO2001066110A2 (fr) PROCEDE DE TRAITEMENT DU DYSFONCTIONNEMENT RENAL AU MOYEN D'INHIBITEURS DE sPLA¿2?
JPH1077226A (ja) βアミロイド蛋白誘発細胞毒性保護作用剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005774727

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005774727

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11660522

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载